We are monitoring the impact of COVID-19 on Latin America Psoriasis Drugs Market Get in touch with us for detailed analysis Know More
Share on

Latin America Psoriasis Drugs Market Research Report - Segmented By Drug Type, Route of Administration, Target, & Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - industry Analysis on Size, Share, Trends and Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1639
Pages: 140

Latin America Psoriasis Drugs Market Size (2022 to 2027)

The Latin American Psoriasis Drugs Market is expected to grow USD 1.06 billion by 2027 from USD 0.74 billion in 2022, showcasing a CAGR of 7.41% from 2022 to 2027.

Strep throat, cold, dry weather, wounds, scrapes, bug bites, severe sunburn, stress, smoking and second-hand smoke, family history of psoriasis, and heavy alcohol consumption are some of the factors and diseases that can cause psoriasis.

The rising prevalence of psoriasis has raised the use of various psoriatic pharmaceutical products and therapies across Latin America, fueling the expansion of the psoriasis pharmaceuticals market. In addition, Y-O-Y growth in the geriatric population in the Latin American region is one of the significant factors promoting the psoriasis drugs market in this region. Furthermore, the psoriasis drugs market in the Latin American region is further predicted to be growing due to an increase in psoriasis research and pipeline products and an increase in disease burden and demand for psoriasis treatments in emerging nations.

However, the market's growth is projected to be hampered by the harsh side effects of most available medications and the high cost of therapy. Though the efficacy of drugs supports market growth in treating the condition, undesirable market considerations such as the high cost of psoriasis therapy may hinder the market growth. In addition, people are becoming more prone to this ailment due to factors such as changing lifestyles and greater predisposition toward alcohol drinking and smoking, bad diets, and sedentary living.

This research report on the Latin American psoriasis drugs market has been segmented and sub-segmented into the following categories:

By Drug Type:

  • Pharmaceuticals
  • Biopharmaceuticals

By Route of Administration: 

  • Topical
  • Systemic
    • Oral
    • Intravenous
    • Others

By Target: 

  • Tumour Necrosis Factor (TNF)
  • Phosphodiesterase Type 4 (PDE4)
  • Interleukin

By Country: 

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Geographically, Latin America accounted for a moderate share of the worldwide market in 2020. However, it is forecasted to accelerate at a healthy CAGR during the forecast period.  Due to the high prevalence of psoriasis in Latin America and the rise in the geriatric population, the market in this region is expected to experience prominent growth. This regional market for psoriasis drugs is moderately competitive, with several significant competitors. In terms of market share, the market is currently dominated by a few leading companies. Companies are focusing on expanding their business in growing regions or emerging markets, such as Mexico, Brazil, and Argentina, using partnerships and acquisitions to produce new goods.

In the Latin American market, the Mexican market is predicted to dominate during the forecast period due to the favorable government efforts, well-developed healthcare infrastructure.


Companies playing an influential role in the Latin American Psoriasis Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck, and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).


                1.1 Market Definition 

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods       

                1.4 General Study Assumptions

2. Research Methodology           

                2.1 Introduction            

                2.2 Research Phases   

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design      

                2.4 Study Timeline       

3. Overview       

                3.1 Executive Summary

                3.2 Key Inferences      

                3.3 Epidemology           

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)    

                4.1 Market Drivers       

                4.2 Market Restraints 

                4.3 Key Challenges      

                4.4 Current Opportunities in the Market           

5. Market Segmentation              

                5.1 Drug Type

                                5.1.1 Introduction                           

                                5.1.2 Pharmaceuticals                   

                                5.1.3 Biopharmaceuticals                             

                                5.1.4  Y-o-Y Growth Analysis, By Drug Type                          

                                5.1.5  Market Attractiveness Analysis, By Drug Type                        

                                5.1.6  Market Share Analysis, By Drug Type                         

                5.2 Route of Administration    

                                5.2.1 Introduction                           

                                5.2.2 Topical                      

                                5.2.3 Systemic                  




                                5.2.4  Y-o-Y Growth Analysis, By Route of Administration                              

                                5.2.5  Market Attractiveness Analysis, By Route of Administration                            

                                5.2.6  Market Share Analysis, By Route of Administration                             

                5.3 Target        

                                5.3.1 Introduction                           

                                5.3.2 Tumour Necrosis Factor (TNF)                        

                                5.3.3 Phosphodiesterase Type 4 (PDE4)                

                                5.3.4 Interleukin                              

                                5.3.5 Others                      

                                5.3.6  Y-o-Y Growth Analysis, By Target                 

                                5.3.7  Market Attractiveness Analysis, By Target                               

                                5.3.8  Market Share Analysis, By Target                 

6. Geographical Analysis              

                6.1 Introduction            

                                6.1.1 Regional Trends                    

                                6.1.2 Impact Analysis                     

                                6.1.3 Y-o-Y Growth Analysis                        

    By Geographical Area     

    By Product           

    By Type 

    By Application    

    By Indication       

                                6.1.4  Market Attractiveness Analysis                     

    By Geographical Area     

    By Product           

    By Type 

    By Application    

    By Indication       

                                6.1.5  Market Share Analysis                      

    By Geographical Area     

    By Product           

    By Type 

    By Application    

    By Indication       

                6.2 Brazil          

                6.3 Mexico      

                6.4 Rest of Latin America          

7.Strategic Analysis        

                7.1 PESTLE analysis      

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis           

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

8.Market Leaders' Analysis         

                8.1 Johnson & Johnson

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Financial analysis                  

                                8.1.4 Recent Developments                       

                                8.1.5 SWOT analysis                       

                                8.1.6 Analyst View                          

                8.2 Novartis International AG

                8.3 Pfizer Inc  

                8.4 Merck and Co. Inc

                8.5 Celgene Corporation           

                8.6 Janssen Biotech Inc              

                8.7 Stiefel Laboratories Inc       

                8.8 Takeda Pharmaceutical Company Limited  

                8.9 Amgen      

                8.10 AbbVie    

9.Competitive Landscape            

                9.1 Market share analysis         

                9.2 Merger and Acquisition Analysis    

                9.3 Agreements, collaborations and Joint Ventures      

                9.4 New Product Launches      

10.Market Outlook and Investment Opportunities          


                a) List of Tables

                b) List of Figures           

  1. Latin America Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  2. Latin America Oral Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  3. Latin America Intravenous Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  4. Latin America Others Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  5. Brazil Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  6. Argentina Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  7. Mexico Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports




pdf excel


pdf excel powerbi




What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.

Talk to our analyst and get customised report done according to your research needs


Check if you can avail any discount. Submit your details and our team will get back to you.


Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?

Find it too expensive?

Click for Request Sample